Company intelligence / Profile preview

HealthCode

Shanghai, Minhang District, Shanghai, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Kangma-Healthcode has demonstrated large-scale, industrial cell-free protein synthesis using yeast systems, reaching bioreactor volumes up to 100,000 liters and commercializing kits for research and screening. Its ACE2 inhibitor was used during the COVID-19 pandemic and new GLP-1 variants and hemoglobin products are near commercial launch.

Therapeutic areas: Infectious DiseasesMetabolic DisordersHematologyOtherDermatology
Modalities: ProteinRecombinant proteinEnzymeSmall molecule (purification tools and reagents)Antibody (possible, based on applications)
Industry: Biotech

Partnerships

Some technical collaborations in China; specifics not publicly disclosed

Beyond the preview

Go deeper on HealthCode.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealthCode.

Explore the full profile